Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 1.48M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -7.94M | Forward P/E | -0.01 | EPS next Y | - | 50D Avg Chg | -99.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -99.00% |
| Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -100.00% |
| Recommedations | - | Quick Ratio | 0.09 | Shares Outstanding | 546.65M | 52W Low Chg | 4.00% |
| Insider Own | - | ROA | -62.00% | Shares Float | 7.23M | Beta | -16.57 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00270 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 222,264 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 29,638,196 | Change | -18.18% |
About INSPYR THERAPEUTIC
Inspyr Therapeutics, Inc., a pharmaceutical company, focuses on the research and development of therapeutics for the treatment of cancer. Its immune-oncology lead asset is RT-AR001, an adenosine A2B receptor antagonist for tumor infiltration. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was incorporated in 2003 and is based in Westlake Village, California.